

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



## Consolidated Financial Results for the Three Months Ended June 30, 2025 [Japanese GAAP]

July 31, 2025

Company name: EIKEN CHEMICAL CO.,LTD.

Listing: Tokyo Stock Exchange

Securities code: 4549

URL: <https://www.eiken.co.jp/en/>

Representative: Yuji Segawa

President & CEO

Inquiries: Tomohiro Kudo

Executive Officer

Telephone: +81-3-5846-3379

Scheduled date to commence dividend payments: -

Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

### 1. Consolidated Financial Results for the Three Months Ended June 30, 2025 (April 1, 2025 to June 30, 2025)

#### (1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2025	10,197	7.1	800	37.2	813	26.8	600	23.4
June 30, 2024	9,519	(3.5)	583	(44.6)	641	(41.0)	486	(36.8)

(Note) Comprehensive income: Three months ended June 30, 2025: ¥ 605 million [ 10.6%]  
Three months ended June 30, 2024: ¥ 547 million [ (31.4)%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2025	18.21	18.04
June 30, 2024	14.07	13.95

#### (2) Consolidated Financial Position

	Total assets	Net assets	Capital adequacy ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
June 30, 2025	59,496	41,754	69.6	1,266.29
March 31, 2025	62,372	43,598	69.3	1,294.08

(Reference) Equity: As of June 30, 2025: ¥ 41,396 million  
As of March 31, 2025: ¥ 43,240 million

## 2. Dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	-	26.00	-	27.00	53.00
Fiscal year ending March 31, 2026	-				
Fiscal year ending March 31, 2026 (Forecast)		29.00	-	29.00	58.00

(Note) Revision to the forecast for dividends announced most recently: None

(Note) Breakdown of the 1st quarter dividend for the fiscal year ending March 31, 2026 :

Commemorative dividend - yen  
Special dividend - yen

## 3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2026(April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending September 30, 2025	21,200	7.5	2,120	35.3	2,050	20.7	3,030	131.4	92.69
Full year	42,200	4.1	3,250	8.3	3,100	(3.1)	3,770	69.2	115.32

(Note) Revision to the financial results forecast announced most recently: None

\* Notes:

(1) Significant changes in the scope of consolidation during the period: None

Newly included: - (Company name: )  
Excluded: - (Company name: )

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement

- 1) Changes in accounting policies due to revisions to accounting standards and other regulations: None
- 2) Changes in accounting policies due to other reasons: None
- 3) Changes in accounting estimates: None
- 4) Restatement: None

(4) Number of issued shares (common shares)

1) Total number of issued shares at the end of the period (including treasury shares):

June 30, 2025: 38,541,438 shares  
March 31, 2025: 38,541,438 shares

2) Number of treasury shares at the end of the period:

June 30, 2025: 5,850,078 shares  
March 31, 2025: 5,127,632 shares

3) Average number of shares outstanding during the period:

Three months ended June 30, 2025: 32,985,383 shares  
Three months ended June 30, 2024: 34,597,930 shares

\* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

## Table of Contents - Attachments

1. Overview of Consolidated Business Performance .....	2
(1) Summary of Consolidated Business Performance for The First Quarter of The Current Fiscal Year .....	2
(2) Summary of Consolidated Financial Position for The First Quarter of The Current Fiscal Year .....	2
(3) Qualitative Information Regarding Forecasts for Consolidated Business Performance .....	3
2. Quarterly Consolidated Financial Statements and Primary Notes .....	4
(1) Quarterly Consolidated Balance Sheet .....	4
(2) Quarterly Consolidated Statements of Income and Comprehensive Income .....	6
Quarterly Consolidated Statements of Income	
For the three months .....	6
Quarterly Consolidated Statements of Comprehensive Income	
For the three months .....	7
(3) Notes to Quarterly Consolidated Financial Statements .....	8
(Notes on going concern assumption) .....	8
(Accounting methods adopted particularly for the preparation of quarterly consolidated financial statements) .....	8
(Notes in case of significant changes in shareholders' equity) .....	8
(Notes on Cash Flow Statement) .....	8
(Segment information) .....	8
(Significant subsequent events) .....	8

## 1. Overview of Consolidated Business Performance

### (1) Summary of Consolidated Business Performance for The First Quarter of The Current Fiscal Year

During the first quarter of the current fiscal year, the domestic and overseas economies remained unstable due to surging resource prices, geopolitical risks, U.S. trade policies, and monetary policies of major countries.

The business environment became increasingly severe in the clinical diagnostics industry due to continued measures to cap medical expenses and rising costs such as for logistics and raw material procurement, etc., on account of yen depreciation and high crude oil prices. Corporations are being forced to focus on greater cost competitiveness and to actively expand into overseas markets.

In the context of this business environment, the Eiken Group is implementing key measures focused on the three key business fields of “Contribution to cancer prevention and treatment,” “Contribution to the eradication and control of infectious diseases,” and “Provision of products and services useful for health care,” under the slogan “Challenges to Innovation” in accordance with the Medium-term Management Plan established based on the Group’s management framework “Eiken Road Map 2030.” The Group is striving to fundamentally transform its business to strengthen its earnings base.

In addition, as a Group with a mission to protect the health of people worldwide, the Eiken Group is addressing issues not only in “Medical” but also in the “Environment,” “Society,” and “Governance.” Through this, we strive to further enhance our corporate value and achieve a sustainable society.

The net sales for the consolidated fiscal year under review increased to 10,197 million yen (up 7.1% year-on-year) due to strong growth in overseas sales. For net sales by product class and type, sales of microbiological testing reagents were 1,081 million yen (up 2.2% year-on-year), and sales of urinalysis reagents were 1,187 million yen (up 5.9% year-on-year) due to growth in sales of test strips for overseas markets. Sales of immunological and serological reagents were 5,956 million yen (up 6.3% year-on-year) due to strong sales of fecal immunochemical test reagents for overseas markets and products introduced and sold from Tosoh Corporation. Sales of clinical chemistry reagents were 149 million yen (down 0.8% year-on-year), and sales of the equipment and culture medium for food and environment related category were 473 million yen (down 7.5% year-on-year). Sales in other category (medical devices, genetic-related products, etc.) were 1,347 million yen (up 25.6% year-on-year) due to increased sales of medical devices for overseas markets and genetic-related products for domestic markets. Overseas sales were 2,763 million yen (up 30.7% year-on-year) due to strong growth in sales of fecal immunochemical test reagents, urinalysis reagents, and medical devices.

Regarding profit, due to the increase in overseas sales, operating profit was 800 million yen (up 37.2% year-on-year), ordinary profit was 813 million yen (up 26.8% year-on-year), and profit attributable to owners of parent was 600 million yen (up 23.4% year-on-year).

### (2) Summary of Consolidated Financial Position for The First Quarter of The Current Fiscal Year

The financial position at the end of the first quarter of the consolidated accounting period under review was as follows.

When compared to the end of the previous consolidated fiscal year, total assets decreased by 2,875 million yen, liabilities decreased by 1,032 million yen, and net assets decreased by 1,843 million yen.

Major increases and decreases in the category of assets were a decrease of 5,204 million yen in cash and deposits. In addition, property, plant and equipment increased by 1,133 million yen due to the construction of the new manufacturing building at Nogi Division. In the category of liabilities, notes and accounts payable - trade decreased by 392 million yen. In the category of net assets, despite the recording of profit attributable to owners of parent, shareholders' equity decreased by 1,847 million yen due to the payment of dividends and acquisition of treasury shares.

As a result, the equity ratio increased from 69.3% at the end of the previous fiscal year to 69.6%.

(3) Qualitative Information Regarding Forecasts for Consolidated Business Performance

For the consolidated financial results forecasts for the six months ending September 30, 2025 and the consolidated fiscal year ending March 31, 2026, there has been no change in the financial forecast announced on May 13, 2025.

## 2. Quarterly Consolidated Financial Statements and Primary Notes

### (1) Quarterly Consolidated Balance Sheet

(Millions of yen)

	As of March 31, 2025	As of June 30, 2025
<b>Assets</b>		
Current assets		
Cash and deposits	9,873	4,669
Notes and accounts receivable - trade, and contract assets	10,928	11,177
Electronically recorded monetary claims - operating	812	601
Merchandise and finished goods	4,576	4,665
Work in process	2,140	2,136
Raw materials and supplies	1,783	2,093
Other	1,423	1,896
Allowance for doubtful accounts	(7)	(7)
Total current assets	31,532	27,232
Non-current assets		
Property, plant and equipment		
Buildings and structures	26,311	33,003
Accumulated depreciation	(14,726)	(14,912)
Buildings and structures, net	11,585	18,090
Machinery, equipment and vehicles	8,338	8,324
Accumulated depreciation	(6,469)	(6,586)
Machinery, equipment and vehicles, net	1,869	1,738
Tools, furniture and fixtures	5,903	5,915
Accumulated depreciation	(4,973)	(5,070)
Tools, furniture and fixtures, net	929	844
Land	1,928	1,928
Leased assets	333	331
Accumulated depreciation	(124)	(140)
Leased assets, net	208	191
Construction in progress	5,600	460
Total property, plant and equipment	22,121	23,254
Intangible assets	670	618
Investments and other assets		
Long-term time deposits	3,000	3,000
Other	5,071	5,413
Allowance for doubtful accounts	(23)	(23)
Total investments and other assets	8,048	8,390
Total non-current assets	30,840	32,263
Total assets	62,372	59,496

(Millions of yen)

	As of March 31, 2025	As of June 30, 2025
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable - trade	5,251	4,858
Electronically recorded obligations - operating	3,238	3,225
Income taxes payable	401	257
Asset retirement obligations	121	121
Provision for bonuses	671	343
Other	4,692	4,543
Total current liabilities	14,376	13,349
Non-current liabilities		
Bonds payable	3,000	3,000
Asset retirement obligations	16	63
Other	1,381	1,328
Total non-current liabilities	4,397	4,391
Total liabilities	18,773	17,741
Net assets		
Shareholders' equity		
Share capital	6,897	6,897
Capital surplus	7,892	7,892
Retained earnings	34,700	34,399
Treasury shares	(6,756)	(8,302)
Total shareholders' equity	42,734	40,886
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	0	35
Foreign currency translation adjustment	338	319
Remeasurements of defined benefit plans	166	154
Total accumulated other comprehensive income	505	510
Share acquisition rights	358	358
Total net assets	43,598	41,754
Total liabilities and net assets	62,372	59,496

## (2) Quarterly Consolidated Statements of Income and Comprehensive Income

## Quarterly Consolidated Statement of Income (For the three months)

(Millions of yen)

	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Net sales	9,519	10,197
Cost of sales	5,566	6,094
Gross profit	3,953	4,103
Selling, general and administrative expenses	3,369	3,302
Operating profit	583	800
Non-operating income		
Interest income	2	4
Dividend income	3	0
Rental income	3	2
Subsidy income	31	27
Foreign exchange gains	18	2
Other	11	8
Total non-operating income	70	45
Non-operating expenses		
Interest expenses	4	4
Share of loss of entities accounted for using equity method	-	23
Other	8	4
Total non-operating expenses	12	32
Ordinary profit	641	813
Extraordinary income		
Gain on sale of non-current assets	-	0
Gain on sale of investment securities	3	-
Total extraordinary income	3	0
Extraordinary losses		
Loss on sale and retirement of non-current assets	0	0
Total extraordinary losses	0	0
Profit before income taxes	644	814
Income taxes	158	214
Profit	486	600
Profit attributable to non-controlling interests	-	-
Profit attributable to owners of parent	486	600



Quarterly Consolidated Statement of Comprehensive Income (For the three months)

(Millions of yen)

	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Profit	486	600
Other comprehensive income		
Valuation difference on available-for-sale securities	(2)	34
Foreign currency translation adjustment	72	(18)
Remeasurements of defined benefit plans, net of tax	(10)	(12)
Total other comprehensive income	60	4
Comprehensive income	547	605
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	547	605
Comprehensive income attributable to non-controlling interests	-	-

(3) Notes to Quarterly Consolidated Financial Statements

(Notes on going concern assumption)

Not applicable.

(Accounting methods adopted particularly for the preparation of quarterly consolidated financial statements)

(Tax expense calculation)

Tax expenses on profit before income taxes are calculated by multiplying profit before income taxes by the reasonably estimated effective tax rate for the consolidated fiscal year including the first quarter of the consolidated accounting period under review after applying tax effect accounting.

(Notes in case of significant changes in shareholders' equity)

(Acquisition of treasury shares)

In accordance with resolution of a meeting of the Board of Directors held on October 31, 2024, the Company acquired 722,400 treasury shares. As a result, for the first quarter of the current fiscal year, treasury shares increased by 1,546 million yen.

(Notes on Cash Flow Statement)

Quarterly consolidated statements of cash flows for the first quarter of the current fiscal year are not prepared.

Depreciation (Including depreciation of intangible assets.) for the first quarter of the current fiscal year is as follows.

	(Millions of yen)	
	Previous consolidated fiscal year (From April 1, 2024 to June 30, 2024)	Current consolidated fiscal year (From April 1, 2025 to June 30, 2025)
Depreciation	546	548

(Segment information)

I Previous consolidated fiscal year (From April 1, 2024 to June 30, 2024)

The Group is a single segment of the reagents business, so it is omitted.

II Current consolidated fiscal year (From April 1, 2025 to June 30, 2025)

The Group is a single segment of the reagents business, so it is omitted.

(Significant subsequent events)

In accordance with resolution of a meeting of the Board of Directors held on May 13, 2025, the Company resolved to transfer all equity interests in its specified subsidiary, EIKEN CHINA CO., LTD., and entered into an equity transfer agreement on July 31, 2025.

For details, please refer to the “(Update on Disclosed Matter) Notice Concerning Transfer of Equity Interests of Consolidated Subsidiary and Recording of Extraordinary Income” announced on July 31, 2025.